Yi Feng Hou
Fudan University
27 Papers
185 Citations
Yi Feng Hou is an academic researcher from Fudan University. The author has contributed to research in topics: Breast cancer & Metastasis. The author has an hindex of 12, co-authored 21 publications.
Chat about Author
Papers
Study on predictors of long term results for neo-adjuvant chemotherapy in locally advanced breast cancer
Ou Huang,Can Ming Chen,Jia yi Wu,Zhen Hu,Yi Feng Hou,Jia Xin Zhang,Guang Yu Liu,Gen Hong Di,Jin Song Lu,Jiong Wu,Zhi Min Shao,Zhen Zhou Shen,Kun Wei Shen +12 more
TL;DR: Pathological response in primary tumor, pre-Ki-67 and post-K i-67 expression,Pre-ER expression are important predictors of long-term outcome for LABC patients with three cycles of VE regimen before operation.
1
Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.
He Cheng Li,Xian Feng Wen,Yi Feng Hou,Kun Wei Shen,Jong Wu,Jing Song Lu,Zhen Zhou Shen,Zhi Ming Shao +7 more
TL;DR: TAM resulted in additional benefit to premenopausal patients with node-positive ER-positive breast cancer who received the CMF polychemotherapy regimen.
1
•Journal Article
In vitro study of the effects of estrogen receptor beta expression on the biological behavior of a human breast cancer cell line
Yi Feng Hou,Sheng tao Yuan,He Cheng Li,Jiong Wu,Jin Song Lu,Li juan Lu,Gang Liu,Zhen Zhou Shen,Jian Ding,Zhi Min Shao +9 more
TL;DR: ER beta was shown to be able to significantly increase the proliferation and invasion of MDA-MB-435 cells in an estradiol-independent manner and down-regulation of p21 and up- regulation of MMP-9 and Ets-1 may be involved in its mechanisms.
1
Correction to: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.
Xin Zhong Chang,Xin Zhong Chang,Da Qiang Li,Yi Feng Hou,Jiong Wu,Jin Song Lu,Gen Hong Di,Wei Jin,Zhou Luo Ou,Zhen Zhou Shen,Zhimin Shao +10 more
TL;DR: The repeated experimental results are consistent with the previously reported findings in the original study and the functional role for PRDX6 in malignant progression of human cancer including breast cancer has been widely documented and recognized in numerous other studies.
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial
Yin Liu,Yue Gong,Xiu-Zhi Zhu,Guang Yu Liu,Keda Yu,Fan Yang,Li Chen,Min He,Zhengjun Hu,Can Ming Chen,A-Yong Cao,Jun-Jie Li,Yi Feng Hou,G. Di,Jiong Wu,Yizhou Jiang,L. Fan,Zhong-hua Wang,Zhibo Shao +18 more
TL;DR: This randomised phase 3 trial found that adding carboplatin to adjuvant chemotherapy significantly improved disease-free and overall survival in high-risk, early-stage triple-negative breast cancer patients, with a reduced risk of early recurrence.